Original article(s) on EXBulletin and Financial Times
The science behind this subject has become mainstream in recent years. Excellent BBC documentary Psychedelic trial We explored the implications of major research at Imperial College. Michael Pollan 2018 Books How to change your mind It has sparked a debate about the use of these substances to help with mental illness. And neuroscientist and podcaster Sam Harris is discussing the issues surrounding it in him. It stands to reason program..
The substance at the center of the debate remains banned. There are psilocybin and lysergic acid diethylamide (LSD), also known as magic mushrooms. Many researchers also include MDMA (ecstasy) and ketamine in a wider group, but they have different pathways to the brain.
What causes agitation is the use of these substances to treat psychiatric disorders, especially “treatment-resistant depression” and post-traumatic stress disorder (PTSD). According to scientific journals, 17 record trials were underway in 2021, most of them psilocybin. Nature..
However, the top of the list must be a UK-based pioneer listed in the United States. Compass route (CMPS), It is conducting clinical trials of psilocybin treatment for cases of refractory depression. The pharmaceutical company is focusing on patented treatments for depression and mental health, and Phase 2 trials are well underway.
Next MindMed (MNMD), Listed on the US Nasdaq Exchange in April. The stock got off to a bumpy start, dropping 29% on the first day of trading. However, keep in mind that the company has actually been listed on the Canadian venture Neo Exchange for over a year and has grown more than 10-fold during that time. This is not a bad return for non-income businesses focused on treatments that use substances such as MDMA, LSD and psilocybin.
Prominent investors include Kevin O’Leary on the US entrepreneurial reality show Shark tank In addition to Bruce Linton, founder of the cannabis company Canopy Growth, Wall Streetbets on the Reddit forum has a long list of day traders busy selling stocks.
Many analysts also appreciate Seelos Therapeutics (SEEL) There are two clinical stage products focused on central nervous system (CNS) distress. We use SLS-002 (ketamine) to treat suicidal patients with major depressive disorder. There are also treatments for some rare genetic disorders, including muscular dystrophy.
Mention should go again Field Trip Health, (FTRP) It went public in Canada at the end of last year and has set up a clinic for low doses of ketamine as an antidepressant. We aim to conduct another Phase 1 trial of psychedelic treatment by 2022.
In a detailed market survey, London-based alternative investment firm Ocean Wall said Saibin, Currently, we are working on a Phase 2 clinical trial to study the use of psilocybin for major depressive disorder. The study enrolls 120 patients taking psilocybin four times over a four-month period.
Above excepts only.
